International Journal of Community Medicine and Public Health | November 2018 | Vol 5 | Issue 11 Page 4853 International Journal of Community Medicine and Public Health Shukla A et al. Int J Community Med Public Health. 2018 Nov;5(11):4853-4857 http://www.ijcmph.com pISSN 2394-6032 | eISSN 2394-6040 Original Research Article Study of correlation of ER, PR, HER2 receptor status in breast cancer at a single tertiary care hospital with emphasis on clinical utility of PR receptor Anjika Shukla 1 , Poonam Singh 2 , Anju Shukla 2 *, Prateek Kumar Mehrotra 3 , Farah Arshad 3 , Priyanka Jain 2 INTRODUCTION Breast cancer which is considered universal worldwide is the most common cancer in female, representing approximately 25% of all cancers. It is also ranked number one cancer among Indian females with age adjusted incidence rate of 25.8 per 1,00,000 women and mortality 12.7 per 1,00,000 women. 1 Treatment of breast cancer includes combined therapy; surgery, radiotherapy, chemotherapy, endocrine therapy, and targeted therapy and so forth. Hormone therapy can be started before surgery (as neoadjuvant therapy) or used after surgery (as adjuvant therapy) or as a prophylactic treatment of high risk populations as in BRCA mutation carriers. Evaluation of hormone receptor on surgically resected specimen or core biopsy material is essential to ABSTRACT Background: The receptor status of breast cancer, including ER, PR and HER 2, play a crucial role in the development of treatment plan of breast cancer. Clinical utility of ER as a predictive biomarker to identify patients likely to benefit from hormonal therapy is well established, added value of PR is less defined. This study aim to know the demography of breast cancer and to document the status of ER, PR and HER 2 status in the north Indian population, as catered by single tertiary care hospital in Lucknow, Uttar Pradesh. Methods: All the patients of breast cancers where surgery or core biopsy was performed for invasive breast carcinoma followed by evaluation of ER, PR and HER 2 status were included in the study from January 2014 to June 2018. Cases were analyzed retrospectively for documentation of ER, PR and HER2 status, using American society of Clinical Oncology/College of American Pathologists (ASCO/CAP) interpretation guidelines. Results: 112 patients were included in the study with mean age of 53.70±12.47. Most common histological type was invasive carcinoma of no special type. 43.75% cases were ER+/PR+, 5.35% were ER+/PR-, and 50.89% were ER- /PR-. ER-/PR+ status was seen in none of our cases. Correlation of ER and PR with HER 2 was possible in 90 cases and triple negative breast cancer (TNBC) status was observed in 32.2% of cases. Conclusions: Demography and ER positivity and incidence of TNBC is not different from rest of India, however the clinical utility for evaluation of PR receptor is to be further investigated. Keywords: Breast carcinoma, Estrogen, Progesterone, HER 2 receptor 1 School of Bioscience and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India 2 Department of Laboratory Medicine, 3 Department of Breast and Endocrine surgery, Sahara Hospital, Lucknow, Uttar Pradesh, India Received: 21 August 2018 Revised: 27 September 2018 Accepted: 29 September 2018 *Correspondence: Dr. Anju Shukla, E-mail: anjushukla2012@gmail.com Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20184584